"Carol Davila" University of Medicine and Pharmacy of Bucharest, 050474 Bucharest, Romania.
Cardiology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Biomolecules. 2023 Feb 8;13(2):321. doi: 10.3390/biom13020321.
Both cardiovascular disease and cancer continue to be causes of morbidity and mortality all over the world. Preventing and treating heart disease in patients undergoing cancer treatment remain an important and ongoing challenge for improving the lives of cancer patients, but also for their survival. Despite ongoing efforts to improve patient survival, minimal advances have been made in the early detection of cardiovascular disease in patients suffering from cancer. Understanding the communication between cancer and cardiovascular disease can be based on a deeper knowledge of the molecular mechanisms that define the profile of the bilateral network and establish disease-specific biomarkers and therapeutic targets. The role of exosomes, microvesicles, and apoptotic bodies, together defined as extracellular vesicles (EVs), in cross talk between cardiovascular disease and cancer is in an incipient form of research. Here, we will discuss the preclinical evidence on the bilateral connection between cancer and cardiovascular disease (especially early cardiac changes) through some specific mediators such as EVs. Investigating EV-based biomarkers and therapies may uncover the responsible mechanisms, detect the early stages of cardiovascular damage and elucidate novel therapeutic approaches. The ultimate goal is to reduce the burden of cardiovascular diseases by improving the standard of care in oncological patients treated with anticancer drugs or radiotherapy.
心血管疾病和癌症仍然是全世界发病率和死亡率的原因。在癌症治疗过程中预防和治疗心脏病仍然是提高癌症患者生活质量、提高其生存率的重要和持续的挑战。尽管人们一直在努力提高患者的生存率，但在癌症患者心血管疾病的早期检测方面几乎没有取得进展。了解癌症和心血管疾病之间的交流，可以基于对定义双边网络特征的分子机制的更深入了解，并建立特定于疾病的生物标志物和治疗靶点。外泌体、微泡和凋亡小体（统称为细胞外囊泡，EVs）在心血管疾病和癌症之间的交叉对话中的作用处于研究的初始阶段。在这里，我们将通过一些特定的介质（如 EVs）讨论癌症和心血管疾病（尤其是早期心脏变化）之间的临床前证据。研究基于 EV 的生物标志物和疗法可能会揭示负责的机制，检测心血管损伤的早期阶段，并阐明新的治疗方法。最终目标是通过改善接受抗癌药物或放射治疗的肿瘤患者的护理标准来减轻心血管疾病的负担。
